pharma news today obesity drugs glp-1 Could weight-loss eat the world? Growth, Volume, Price: The Skinny

RCT, randomized controlled study

AstraZeneca plc (UK) Established in 1999, AstraZeneca has played an important role in expanding treatment options in type 2 diabetes through its work in GLP-1 and related metabolic pathways

Tirzepatide has an obviously lower affinity with GIPR than GIP does (pIC 50 : 6.70 vs 7.87), and its cAMP activity is approximately equal to that of GIP

"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes"

For reference on what standard titration looks like, the starting dose of tirzepatide guide covers what patients typically experience in the early weeks

Metabolic reprogramming in kidney diseases: evidence and therapeutic opportunities